How to Evaluate a Pharma Contract Sales Organization

In 2024, a specialty pharma company signed a CSO contract for a cardiology product launch. The agreement covered 38 territories across the Southeast. Eight months in, they were locked into a 14-month minimum commitment with reps who had averaged fewer than 60 details per week and couldn't name the top five prescribers in their territories from memory.

The CSO had disclosed everything. It was in the contract. But the contract was 51 pages, and nobody had read page 34, which is where the performance remediation process was buried — a process that required six weeks of documented underperformance before any corrective action could trigger.

I see versions of this situation more than I should. And the companies involved aren't naive. They're experienced pharma commercial teams who moved too fast during a launch timeline and treated CSO selection the way you'd treat an approved vendor procurement process, not the way you'd treat hiring the people responsible for your drug's first-year market share.

Here's the evaluation framework I'd use if I were on the other side of that table.

The six questions that surface the real picture

Most CSO sales conversations are competent. They'll show you rep credentials, territory coverage maps, therapeutic area experience. That information is useful but insufficient. The questions that actually differentiate are the ones the CSO isn't expecting.

Question 1: What percentage of your current rep roster worked in branded pharmaceutical sales before joining your organization?

A high proportion of experienced branded reps signals a different network than a CSO that primarily recruits from medical device, specialty generics, or hospital distribution backgrounds. The distinction matters because branded pharma relationships — the ones built around pulling prescribers toward formulary-favored products — are hard to transfer from other sales contexts. Ask for the actual number, not a range.

Question 2: What's your average rep tenure, and what's your 12-month turnover rate?

High turnover in a CSO's own workforce is a problem that compounds directly into your launch. A rep who's been with the organization for four months has weaker internal support, weaker training compliance, and weaker accountability than a rep who's been there for three years. Turnover rates above 25% annually in a field sales organization are worth probing hard. Above 35%, I'd treat it as a disqualifying signal.

Question 3: Walk me through a launch where you underperformed against projections. What happened, and what changed?

Every CSO has one. The good ones can tell you specifically what went wrong — was it a territory size miscalculation, a therapeutic area the reps weren't ready for, a prescriber access problem they didn't anticipate? Vague answers here usually mean they either don't track performance at the rep level in enough detail to diagnose problems, or they don't want to tell you what actually happened. Neither is a good sign.

Question 4: What are the specific conditions under which we can exit the contract without penalty?

Not "what's your exit clause" — that question gets you a recitation of the contract terms. "What are the specific conditions" forces them to explain what the remediation process looks like in practice, how long it takes, and what your realistic options are if performance is poor but doesn't technically breach the SLA threshold. If they can't answer this without pulling up the contract, that's information.

Question 5: How do you handle rep replacement when a specific territory rep isn't performing?

Some CSOs treat replacement requests as a client right, others treat them as a negotiation. The difference matters enormously if you're six months into a launch with a rep who isn't building relationships in a key hospital system. Get the specific process in writing, including timelines. "We'll address it promptly" is not a process.

Question 6: Can you provide three client references in our therapeutic category who launched in the past 18 months?

Not clients in general. Not clients with similar product types. Clients who launched branded products in your specific therapeutic area, recently. Then call them. Don't email. Ask what they'd do differently and listen for the hesitations.

Red flags in the response

Beyond the answers themselves, watch how the CSO responds to these questions.

A CSO that answers question four (exit conditions) fluently and without hesitation has been asked it many times and is comfortable with their terms. A CSO that pivots to their client retention rate has just told you their exit clause is not their competitive advantage.

A CSO that reframes question two (turnover) as a strength ("we actively manage out underperformers") without providing the actual number is not going to provide the actual number. Push.

A CSO that can't name specific prescriber-facing challenges from a past launch in your category — not generically, but specifically — has not done a launch in your category recently enough for the experience to be current.

Contract terms worth fighting for

Most CSO contracts are written to protect the CSO. That's not cynical, it's just accurate. The negotiation points that matter most:

Performance-based milestones tied to exit rights. Define specific, measurable metrics — detail frequency, prescriber reach, target decile penetration — with a 90-day review window. If the metrics aren't met, you want a no-penalty exit or a rep replacement option, not a remediation period that lasts longer than a quarter.

Territory-level reporting. Aggregate performance reporting is nearly useless for identifying where problems are. You need individual territory metrics — by rep, by prescriber target, by call frequency — at a minimum monthly cadence. This should be contractual, not a verbal commitment.

Named rep approval rights. Before a rep is deployed in your territory, you should have the right to review their credentials and pharma experience and decline if they don't meet your standards. Some CSOs resist this. The ones that resist it hardest are usually the ones with the weakest available roster in your geography.

Transition assistance language. If the relationship ends — for any reason — you want a 60-day transition period during which the CSO cooperates with handing off accounts, relationship documentation, and call notes. Without this language, you can lose months of account intelligence.

The faster alternative

For companies that want dedicated reps without CSO contract complexity, direct contractor placement is worth the conversation. An experienced pharmaceutical 1099 contractor working a defined territory under a direct agreement gives you the rep dedication of a W-2 hire with faster placement timelines and without 18-month lock-in provisions.

The tradeoff is that you're managing the relationship more directly — there's no CSO infrastructure handling training and compliance oversight. For companies with an existing commercial infrastructure who just need the headcount, this is usually the better arrangement.

For companies launching from scratch without commercial ops in place, a CSO relationship that includes those support functions can make sense — provided you've asked the right questions first.